
- Head and Neck Cancers (Issue 4)
- Volume 3
- Issue 4
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Sylvia Asa, MD, PhD, FRCPC, FCAP, pathologist, Toronto General Hospital/Research Institute, professor, University of Toronto, discusses the ambiguity of certain subtypes of thyroid cancer. Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Asa says researchers are finding different mutations that make these different subtypes what they are. Some of these subtypes include TERT promoter mutations, as well as epigenetic changes such as alterations in the micro RNAs and epigenetic activation or silencing of genes. She says uncovering more information about these mutations and changes could aid in the creation of different therapies.
Articles in this issue
almost 10 years ago
Immunotherapies Gaining Traction in Head and Neck Cancersalmost 10 years ago
Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Carealmost 10 years ago
Link Drawn Between Oral HPV and Risk of Head and Neck Cancersalmost 10 years ago
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Canceralmost 10 years ago
Nivolumab Could Change Head and Neck Cancer Treatment Paradigmalmost 10 years ago
Nivolumab Boosts OS in Phase III in SCCHN Study






































